Spots Global Cancer Trial Database for LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
Official Title: Clinical Trial for the Safety and Efficacy of Sequential of LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
Study ID: NCT04657965
Interventions
Study Description
Brief Summary: A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies
Detailed Description: This is a single arm, open-label, single-center study. This study is indicated for LMP1 positive infectious diseases and hematological malignancies. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 144 patients will be enrolled. Primary objective is to explore the safety, main consideration is dose-related safety.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
